Emanuele Giorgi

Dr. Emanuele Giorgi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Hepatology
Verified
Journal Article
Open access
ASAlexander J. Stockdale
Alexander J. Stockdale
BKBenno Kreuels
Benno Kreuels
MHMarc Y.R. Henrion
Marc Y.R. Henrion
EGEmanuele Giorgi
Emanuele Giorgi
IKIrene Kyomuhangi
Irene Kyomuhangi
AGAnna Maria Geretti
Anna Maria Geretti
There are uncertainties about the epidemic patterns of hepatitis delta virus (HDV) infection and its contribution to the burden of liver disease. We estimated the global prevalence of HDV infection and explored its contribution to the development of cirrhosis and hepatocellular carcinoma (HCC) among hepatitis B surface antigen (HBsAg)-positive people. We searched Pubmed, EMBASE and Scopus for studies reporting on total or IgG anti-HDV among HBsAg-positive people. Anti-HDV prevalence was estimated using a binomial mixed model, weighting for study quality and population size. The population attributable fraction (PAF) of HDV to cirrhosis and HCC among HBsAg-positive people was estimated using random-effects models. We included 282 studies, comprising 376 population samples from 95 countries, which together tested 120,293 HBsAg-positive people for anti-HDV. The estimated anti-HDV prevalence was 4.5% (95% CI 3.6, 5.7) among all HBsAg-positive people and 16.4% (14.6, 18.6) among those attending hepatology clinics. Worldwide, 0.16% (0.11, 0.25) of the general population, totalling 12.0 (8.7, 18.7) million people, were estimated to be anti-HDV positive. Prevalence among HBsAg-positive people was highest in Mongolia, the Republic of Moldova and countries in Western and Middle Africa, and was higher in injecting drug users, haemodialysis recipients, men who have sex with men, commercial sex workers, and those with hepatitis C virus or HIV. Among HBsAg-positive people, preliminary PAF estimates of HDV were 18% (10, 26) for cirrhosis and 20% (8, 33) for HCC. An estimated 12 million people worldwide have experienced HDV infection, with higher prevalence in certain geographic areas and populations. HDV is a significant contributor to HBV-associated liver disease. More quality data are needed to improve the precisions of burden estimates.

22 July 2014 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
HZHonorat Gm Zouré
Honorat Gm Zouré
MNMounkaila Noma
Mounkaila Noma
ATAfework H Tekle
Afework H Tekle
UAUche V Amazigo
Uche V Amazigo
PDPeter J Diggle
Peter J Diggle
JRJan Hf Remme
Jan Hf Remme
The original aim of the African Programme for Onchocerciasis Control (APOC) was to control onchocerciasis as a public health problem in 20 African countries. In order to identify all high risk areas where ivermectin treatment was needed to achieve control, APOC used Rapid Epidemiological Mapping of Onchocerciasis (REMO). REMO involved spatial sampling of villages to be surveyed, and examination of 30 to 50 adults per village for palpable onchocercal nodules. REMO has now been virtually completed and we report the results in two articles. A companion article reports the delineation of high risk areas based on expert analysis. The present article reports the results of a geostatistical analysis of the REMO data to map endemicity levels and estimate the number infected.

8 July 2016 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
DEDileepa Senajith Ediriweera
Dileepa Senajith Ediriweera
AKAnuradhani Kasturiratne
Anuradhani Kasturiratne
APArunasalam Pathmeswaran
Arunasalam Pathmeswaran
NGNipul Kithsiri Gunawardena
Nipul Kithsiri Gunawardena
BWBuddhika Asiri Wijayawickrama
Buddhika Asiri Wijayawickrama
HSHithanadura Janaka De Silva
Hithanadura Janaka De Silva
There is a paucity of robust epidemiological data on snakebite, and data available from hospitals and localized or time-limited surveys have major limitations. No study has investigated the incidence of snakebite across a whole country. We undertook a community-based national survey and model based geostatistics to determine incidence, envenoming, mortality and geographical pattern of snakebite in Sri Lanka. The survey was designed to sample a population distributed equally among the nine provinces of the country. The number of data collection clusters was divided among districts in proportion to their population. Within districts clusters were randomly selected. Population based incidence of snakebite and significant envenoming were estimated. Model-based geostatistics was used to develop snakebite risk maps for Sri Lanka. 1118 of the total of 14022 GN divisions with a population of 165665 (0.8%of the country’s population) were surveyed. The crude overall community incidence of snakebite, envenoming and mortality were 398 (95% CI: 356–441), 151 (130–173) and 2.3 (0.2–4.4) per 100000 population, respectively. Risk maps showed wide variation in incidence within the country, and snakebite hotspots and cold spots were determined by considering the probability of exceeding the national incidence. This study provides community based incidence rates of snakebite and envenoming for Sri Lanka. The within-country spatial variation of bites can inform healthcare decision making and highlights the limitations associated with estimates of incidence from hospital data or localized surveys. Our methods are replicable, and these models can be adapted to other geographic regions after re-estimating spatial covariance parameters for the particular region. Snakebite is a neglected tropical disease which mainly affects the rural poor in tropical countries. There is little reliable data on snakebite, which makes it difficult to estimate the true disease burden. Hospital statistics underestimate numbers of snakebites because a significant proportion of victims in tropical countries seek traditional treatments. On the other hand, time limited or localized surveys may be inaccurate as they may underestimate or overestimate numbers depending on when and where they are performed. To get a truer picture of the situation in Sri Lanka, where snakebites are an important cause of hospital admission, we undertook an island-wide community survey to determine the number of bites, envenomings and deaths due to snakebite in the previous 12 months. We found that there were more than 80,000 bites, 30,000 envenomings and 400 deaths due to snakebite, much more than claimed by official statistics. There was variation in numbers of bites and envenomings in different parts of the country and, using the data from our survey, we were able develop snakebite risk maps to identify snakebite hotspots and cold spots in the country. These maps would be useful for healthcare decision makers to allocate resources to manage snakebite in the country. We used free and open source software and replicable methods, which we believe can be adopted to other regions where snakebite is a public health problem.

3 January 2022 in Malaria Journal
Verified
Journal Article
Open access
PDF file
IKIrene Kyomuhangi
Irene Kyomuhangi
EGEmanuele Giorgi
Emanuele Giorgi
Background: In malaria serology analysis, the standard approach to obtain seroprevalence, i.e the proportion of seropositive individuals in a population, is based on a threshold which is used to classify individuals as seropositive or seronegative. The choice of this threshold is often arbitrary and is based on methods that ignore the age-dependency of the antibody distribution. Methods: Using cross-sectional antibody data from the Western Kenyan Highlands, this paper introduces a novel approach that has three main advantages over the current threshold-based approach: it avoids the use of thresholds; it accounts for the age dependency of malaria antibodies; and it allows us to propagate the uncertainty from the classification of individuals into seropositive and seronegative when estimating seroprevalence. The reversible catalytic model is used as an example for illustrating how to propagate this uncertainty into the parameter estimates of the model. Results: This paper finds that accounting for age-dependency leads to a better fit to the data than the standard approach which uses a single threshold across all ages. Additionally, the paper also finds that the proposed threshold-free approach is more robust against the selection of different age-groups when estimating seroprevalence. Conclusion: The novel threshold-free approach presented in this paper provides a statistically principled and more objective approach to estimating malaria seroprevalence. The introduced statistical framework also provides a means to compare results across studies which may use different age ranges for the estimation of seroprevalence.

1 January 2017 in Journal of Statistical Software
Verified
Journal Article
Open access
EGEmanuele Giorgi
Emanuele Giorgi
PDPeter J. Diggle
Peter J. Diggle
PrevMap: An R Package for Prevalence Mapping

2 July 2016 in Journal of the American Statistical Association
Verified
Journal Article
Closed access
PDPeter J. Diggle
Peter J. Diggle
EGEmanuele Giorgi
Emanuele Giorgi
In low-resource settings, prevalence mapping relies on empirical prevalence data from a finite, often spatially sparse, set of surveys of communities within the region of interest, possibly supplemented by remotely sensed images that can act as proxies for environmental risk factors. A standard geostatistical model for data of this kind is a generalized linear mixed model with binomial error distribution, logistic link, and a combination of explanatory variables and a Gaussian spatial stochastic process in the linear predictor. In this article, we first review statistical methods and software associated with this standard model, then consider several methodological extensions whose development has been motivated by the requirements of specific applications. These include: methods for combining randomized survey data with data from nonrandomized, and therefore potentially biased, surveys; spatio-temporal extensions; and spatially structured zero-inflation. Throughout, we illustrate the methods with disease mapping applications that have arisen through our involvement with a range of African public health programs.